NEW YORK, August 5, 2026 — Leads & Copy — Immuneering Corporation, a late-stage clinical oncology company, today reported its financial results for the second quarter ended June 30, 2026, and provided key business updates. The company highlighted promising results for its lead product candidate, atebimetinib, in the treatment of pancreatic cancer.
In an oral presentation at the ASCO Annual Meeting on June 1, Immuneering reported a median overall survival of 17.3 months in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy. This data from a single-arm Phase 2a study showed atebimetinib combined with modified gemcitabine/nab-paclitaxel (mGnP) to be potentially best-in-class for first-line pancreatic cancer patients, a group now having treatment options.
Additionally, the Phase 2a data revealed that 84% of evaluable patients treated with atebimetinib + mGnP maintained or gained weight at three months. The study also noted that only two categories of treatment-related adverse events occurred at grade 3 or higher in at least 10% of patients, suggesting that debilitating side effects may not be an inevitability for patients.
Immuneering’s pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer is currently underway, with patients being dosed across more than 30 study locations posted to date. The company announced that the first patient was dosed in this global, randomized, open-label trial in June.
Further supporting the potential of atebimetinib, a peer-reviewed publication in Cancer Research details the drug’s broad, durable preclinical activity and favorable tolerability across RAS- and RAF-mutant tumors, along with the preservation of body mass. The article, published in July, characterizes atebimetinib’s differentiated mechanism via Deep Cyclic Inhibition, demonstrating broad antitumor activity in RAS- and RAF-mutant models while resisting RAF-mediated bypass signaling, a common resistance mechanism to other MEK inhibitors. The publication also highlighted atebimetinib’s ability to preserve body mass in a preclinical model of cancer cachexia.
In April, Immuneering presented new genetic data at AACR suggesting atebimetinib’s mechanism can improve durability and survival. Circulating tumor DNA (ctDNA) data from 123 atebimetinib-treated patients indicated that acquired MAPK pathway alterations were rarely observed, suggesting Deep Cyclic Inhibitors have the potential to overcome limitations of conventional MAPK inhibition and offer more sustained clinical benefit while potentially preserving sensitivity to subsequent treatments.
The company also reported the appointment of Andrew Gengos as Chief Financial Officer in June. Mr. Gengos previously served as CFO and Head of Corporate Development at Terns Pharmaceuticals, which was acquired by Merck & Co., Inc. for $6.7 billion. He will lead financial strategy, capital allocation, investor relations, and business and corporate development.
Looking ahead, Immuneering anticipates dosing the first patient in a Phase 2 trial of atebimetinib in combination with anti-PD-1 (cemiplimab) in non-small cell lung cancer in the second half of 2026, with a preliminary data readout expected in late 2027. Additional preclinical data for this combination is expected in Q4 2026. The company plans to begin IND-enabling studies for its next DCI product candidate program by mid-2027 and expects a topline data readout from the MAPKeeper 301 trial by mid-2028.
For the second quarter ended June 30, 2026, Immuneering reported cash, cash equivalents, and marketable securities totaling $182.7 million. This provides an anticipated cash runway into 2029. Research and Development expenses were $14.0 million for the quarter, compared to $10.5 million in the second quarter of 2025, primarily due to increased clinical costs for the atebimetinib program. General and Administrative expenses were $5.0 million, compared to $4.3 million in the prior year’s second quarter, reflecting increased employee and software costs.
The company reported a net loss attributable to common stockholders of $17.3 million, or $0.27 per share, for the second quarter of 2026, compared to a net loss of $14.4 million, or $0.40 per share, for the second quarter of 2025.
Source: Immuneering Corporation
